slightbourne@noblecapitalmarkets.com, Author at Channelchek

SK Hynix Just Completed the Biggest Foreign IPO in U.S. History. It Jumped 14% on Day One

Posted on July 10, 2026July 10, 2026 by [email protected]

SK Hynix began trading on the Nasdaq this morning, and the market’s answer to seven-times oversubscribed demand was immediate. Shares opened at $170, up 14% from the $149 offer price, and were trading as much as 16.7% higher intraday under the temporary ticker SKHYV before the stock moves to its permanent symbol, SKHY, on Monday.

The final numbers on the raise came in at $26.5 billion, slightly below the roughly $28 billion initially targeted but still enough to make this the largest first-time listing by a foreign company in U.S. history, surpassing Alibaba’s American debut. The offering consisted of 177.9 million American depositary receipts, each representing one-tenth of a common share.

The scale of demand tells the real story here. SK Hynix’s South Korea-listed shares have climbed 174% over the past six months and 634% over the past year, and the company’s SEC filing disclosed it now holds 56.4% of the global high-bandwidth memory market, the largest share among the three companies, Micron, Samsung, and SK Hynix, that make this specialized chip. HBM sits directly next to AI processors like Nvidia’s GPUs, holding the data those chips need instantly rather than forcing them to reach across a data center for it. Every major AI buildout depends on it, and there currently isn’t enough to go around.

That shortage, according to industry estimates cited in today’s coverage, could persist into 2030 simply because new fabrication capacity takes years to bring online. It is precisely what SK Hynix’s listing is designed to help fix. Proceeds are earmarked for new manufacturing facilities and equipment, giving U.S. investors a rare direct stake in a name that has mostly been accessible only through Seoul-listed shares.

But the timing carries its own tension. Just three days before this debut, memory stocks including Micron, Samsung, and SK Hynix itself slid into a bear market, a reminder that this industry has a well-earned reputation for violent cycles. Patrick Moorhead, founder of Moor Insights & Strategy, put it bluntly, noting that memory makers were selling chips below cost with negative gross margins only a few years ago before capital expenditure pulled back sharply and demand caught fire again. Micron has responded by locking customers into five-year strategic supply agreements with large upfront payments, a structural shift from the one-year contracts that used to define the industry, aimed at smoothing out exactly this kind of boom-and-bust pattern. Whether that holds the next downturn at bay is an open question nobody can answer yet.

For small and micro-cap investors, SK Hynix itself is now a trillion-dollar company well outside that world. But the moment matters anyway. When the second-largest foreign listing in U.S. history debuts to a 14% pop just days after its own sector fell into bear market territory, it captures the exact push and pull defining the memory trade in 2026: extraordinary current profitability sitting on top of an industry that has never once avoided the cycle eventually turning. The public companies feeding into this supply chain, from equipment makers to specialty materials suppliers, are all trading in that same shadow today.

AZZ (AZZ) – First Quarter FY27 Financial Results Exceed Expectations; Increasing Estimates

Posted on July 10, 2026July 10, 2026 by [email protected]

Friday, July 10, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY 2027 first quarter financial results. AZZ reported adjusted net income of $55.8 million, or $1.85 per share, compared to $53.8 million, or $1.78 per share, during the prior year period. We had forecast adjusted net income of $51.4 million or $1.70 per share. Compared to the first quarter of FY 2026, sales increased 6.3% to $448.5 million. Adjusted EBITDA amounted to $99.5 million compared to our estimate of $96.8 million. Compared to the prior year period, first quarter Metal Coatings sales were up 12.3% to $210.3 million, while Precoat Metal sales increased 1.5% to $238.2 million. First quarter segment adjusted EBITDA margin amounted to 30.3% for Metal Coatings and 21.7% for Precoat Metals.

FY 2027 Corporate Guidance. Management now expects FY 2027 sales in the range of $1.80 to $1.85 billion, compared to previous expectations of $1.725 to $1.775 billion. Adjusted EBITDA is expected to be in the range of $375 to $415 million, compared to prior guidance of $360 to $400 million. Adjusted EPS is now projected to be $6.75 to $7.15 versus prior expectations of $6.50 to $7.00.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

The 30-Year Treasury Just Paid Its Highest Yield Since 2007. Here’s What the Auction Actually Showed

Posted on July 10, 2026July 10, 2026 by [email protected]

The U.S. government sold $25 billion of 30-year Treasury bonds yesterday at a yield of 5.058%, the richest rate on a long bond auction since 2007. That headline number is drawing attention, but the full picture from this week’s auctions is more balanced than the yield alone suggests.

Start with the demand side. Pre-auction trading had the 30-year yield sitting at 5.061% just before the bidding deadline, meaning the final result actually came in slightly better than the market was pricing, a sign that buyers stepped in rather than stepped back. That is generally read as a healthy outcome, not a warning sign. Context matters here too. Existing 30-year bonds have already traded as high as 5.20% earlier this year, so yesterday’s print sits within a range the market has already absorbed rather than representing new, uncharted territory.

A day earlier, the Treasury auctioned $42 billion of 10-year notes, and that result was cleaner still. The auction cleared at 4.58% with a bid-to-cover ratio of 2.59, comfortably above the 2.5 level traders typically use as a benchmark for solid demand. No stress signals, no last-minute yield spike, no indication that investors are hesitant to hold U.S. government debt at current levels. Between the two auctions, the government raised $67 billion this week alone as part of a broader $119 billion week of coupon issuance, and both sales found willing buyers.

The interesting nuance is why the 30-year yield moved more than the 10-year. When the long end of the curve carries a higher premium relative to shorter maturities, it typically reflects investors asking for more compensation to hold debt across multiple decades rather than any concern about near-term credit risk. That’s consistent with straightforward supply and demand dynamics: more long-duration issuance generally requires a higher yield to clear the market, independent of the government’s underlying fiscal position.

The practical relevance for investors runs in a few directions. The 10-year yield is the direct reference point for 30-year mortgage rates, so a 4.58% clearing yield keeps the housing affordability conversation roughly where it has been. For companies that borrow against Treasury benchmarks, and smaller, more leveraged businesses in particular tend to feel rate moves more directly, the cost of long-term borrowing is shaped as much by auction dynamics like these as by anything the Federal Reserve decides at its policy meetings. The Fed sets the front end of the curve through its rate decisions. The long end responds to a separate set of forces, including how much duration the market is being asked to absorb and at what price investors are willing to hold it.

Taken together, this week’s auctions showed a market that is functioning and finding demand, just at a higher price for long-duration debt than it has required in nearly two decades. Whether that becomes a durable new range or eases as issuance patterns shift is something the next several auction cycles will help clarify.

The Magnificent 7 Just Hit Their Cheapest Valuation in Over a Decade

Posted on July 10, 2026July 10, 2026 by [email protected]

For most of the past five years, the Magnificent Seven traded at a persistent and widening premium to the rest of the S&P 500. That premium has now compressed to its lowest level in more than a decade, and the implications for how capital flows through the broader market are significant.

The price-to-earnings multiple premium for the Magnificent Seven relative to the other 493 companies in the S&P 500 has dropped to approximately 10%, according to Morgan Stanley. That figure held above 30% for most of the 2020s. The collapse in relative valuation is not because these companies are struggling operationally. It is because the market is repricing what it is willing to pay for growth when that growth comes at the cost of massive, accelerating capital expenditure with uncertain near-term returns.

What’s Driving the Compression

All seven stocks have underperformed the S&P 500 in 2026 except Alphabet, which has gained 14.5% year to date versus the benchmark’s 8.8% advance. Nvidia, Microsoft, Amazon, Meta, Apple, and Tesla have all lagged the index. For a group that dominated market leadership for the better part of three years, the collective underperformance is striking.

The primary source of investor frustration is capital spending on artificial intelligence infrastructure. The Magnificent Seven’s combined AI-related capital expenditures are projected to exceed $700 billion in 2026, a 70% increase from the prior year. That level of spending is consuming corporate cash generation at a pace that has pushed the group’s collective 12-month forward free cash flow projections sharply below their 2024 peak. Investors are watching these companies pour hundreds of billions into data centers and GPUs while the revenue return on that investment remains difficult to quantify with precision.

Layer on the prospect of a Fed rate hike later this year, which would increase the cost of financing AI projects, and the math behind the underperformance becomes straightforward. Higher rates, lower free cash flow, and uncertain AI monetization timelines are a combination that compresses multiples regardless of how strong the underlying business remains.

The Mirror Image for Small Caps

What makes this data point particularly relevant for ChannelChek’s audience is what happens to the rest of the market when the Magnificent Seven’s gravitational pull weakens. For most of 2023 and 2024, the concentration of capital in seven stocks starved the rest of the equity universe of institutional attention and flows. The top ten companies in the S&P 500 grew to represent more than 35% of the index’s total weight, up from 18% a decade ago. That concentration meant the other 493 companies, and the thousands of smaller companies outside the index entirely, were competing for a shrinking share of investor capital.

That dynamic is now reversing. The Russell 2000 posted its best first half in 35 years, gaining nearly 22% through June. Market breadth has expanded meaningfully, with advancing stocks consistently outnumbering decliners. The equal-weight S&P 500 has outperformed the cap-weighted version. Capital that was previously locked into mega cap technology is rotating into industrials, consumer companies, energy producers, and the broader small cap universe.

The Magnificent Seven premium compressing to 10% is the quantitative proof of what the price action has been saying all year. The trade that dominated markets for the past three years is losing its hold, and the beneficiaries are the companies that were left behind during the concentration era. Many of those companies trade well below the $2 billion market cap threshold and are only now beginning to see the valuation and capital flow benefits of a broadening market.

The Magnificent Seven are not broken. They are just no longer the only game in town. For investors positioned in the rest of the market, that is exactly the environment they have been waiting for.

Wall Street Is Finally Noticing Small Caps

Posted on July 9, 2026July 9, 2026 by [email protected]

JPMorgan announced this week that it is building a new investment banking team dedicated entirely to small-cap dealmaking, targeting companies valued between $100 million and $500 million. The team will sit alongside the bank’s existing middle-market group, which covers companies between $500 million and $1 billion and already employs nearly 400 bankers. According to an internal memo reported by Yahoo Finance, the new group will be based in New York, Los Angeles, Dallas, Chicago, and Atlanta, with plans to hire more than 75 bankers in the near term. It will start by focusing on diversified industries, consumer and retail, and business services, led by new hire Michael Flynn, a veteran middle-market banker.

It is a notable move for a bank of JPMorgan’s size. But for investors who have been paying attention to small and micro caps all year, this is a confirmation, not a discovery.

The Russell 2000 gained nearly 22% in the first half of 2026, its best first-half performance since 1991, outpacing the S&P 500 and Dow’s roughly 9% gains and the Nasdaq’s 13% rise. Every sector in the index finished the first half in positive territory, led by technology, industrials, financials, and healthcare. Analysts have pointed to easing financial conditions, a healthier credit backdrop, and valuations that remain meaningfully discounted relative to large caps as reasons the rally has legs. Small caps also tend to benefit disproportionately once a rate-cutting cycle takes hold, since a larger share of their balance sheets rely on variable or shorter-term financing.

What JPMorgan’s move really signals is that the largest pools of capital are starting to reposition toward a part of the market that has been overlooked for the better part of a decade. Big banks do not build out dedicated coverage teams on a whim. They do it when deal flow, IPO activity, and client demand justify the headcount, and that kind of infrastructure typically follows smart money into a space rather than leading it there.

That kind of institutional attention tends to arrive with real consequences for pricing. More bankers covering the space usually means more IPOs, more M&A activity, more equity research, and ultimately more liquidity flowing into names that have traded at a discount simply because fewer people were watching them closely. Small caps have historically underperformed for years at a time before snapping back sharply once capital rotates in, and that rotation is often driven by exactly this kind of institutional repositioning rather than a single catalyst.

For investors, the takeaway is straightforward. Institutional capital chasing small caps tends to compress the valuation gap that made the space attractive in the first place. Getting positioned ahead of that convergence, rather than after it, is where the real opportunity sits. With small caps already outperforming and now drawing this kind of attention from a bank the size of JPMorgan, the window to act on that discount looks like it will not stay open indefinitely.

MAIA Biotechnology (MAIA) – First Data From Phase 2 Part C Trial Shows Data Consistent With Earlier Studies

Posted on July 9, 2026July 9, 2026 by [email protected]

Thursday, July 09, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Data From Part C Announced. MAIA announced data from Part C (Expansion stage) of its Phase 2 THIO-101 trial in non-small cell lung cancer (NSCLC). This open-label stage of the trial tests the combination of ateganosine and cemiplimab (Libtayo, from Regeneron) as a third-line (3L) therapy for patients with advanced disease that no longer respond to other therapies. The data after the first evaluation have a Disease Control Rate (DCR) of 90.5% (19 out of 21 patients), compared with published rates of 25% to 35%. We view this as a good sign that patient responses are consistent with previous data.

Design Of the Phase 2 THIO-101 Trial. The Phase 2 THIO-101 Expansion stage is the third part of the Phase 2 trial. Part A tested safety, while Part B was for dose optimization and selection. Part C is currently testing the combination of the 180 mg dose of ateganosine with cemiplimab. If positive, the data could be used to apply for accelerated approval from the FDA.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

AZZ (AZZ) – First Quarter FY27 Financial Results Exceed Expectations; Guidance Raised

Posted on July 9, 2026July 9, 2026 by [email protected]

Thursday, July 09, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY 2027 First Quarter Financial Results. AZZ reported adjusted net income of $55.8 million, or $1.85 per share, compared to $53.8 million, or $1.78 per share, during the prior year period. We had forecast adjusted net income of $51.4 million or $1.70 per share. Compared to the first quarter of FY 2026, sales increased 6.3% to $448.5 million. Adjusted EBITDA amounted to $99.5 million compared to our estimate of $96.8 million. Compared to the prior year period, first quarter Metal Coatings sales were up 12.3% to $210.3 million, while Precoat Metal sales increased 1.5% to $238.2 million. First quarter segment adjusted EBITDA margin amounted to 30.3% for Metal Coatings and 21.7% for Precoat Metals.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Why the Fed’s July Meeting Matters More for Small Caps Than Anyone Else

Posted on July 9, 2026July 9, 2026 by [email protected]

The Russell 2000 has gained 33.8% over the past twelve months, comfortably beating the S&P 500’s 20% return, and just posted its best first-half performance since 1991. That’s the headline every small-cap investor has been celebrating. The number underneath it tells a different story.

Interest expense now consumes 31% of EBITDA for companies in the Russell 2000, the heaviest debt-servicing burden these companies have carried in at least six years. Nearly 30% of small-cap corporate debt sits on floating rates, meaning it resets with whatever the Federal Reserve does next rather than staying locked in at yesterday’s borrowing costs. By comparison, floating-rate debt makes up only about 7% of S&P 500 balance sheets, and large-cap interest expense sits at just 6.7% of EBITDA. Small caps have always carried more leverage relative to earnings than their large-cap counterparts. What’s changed is how expensive that leverage has become to service, and how much more exposed small caps are to the Fed’s next move than the rest of the market.

The mechanics here matter more for small caps than almost anywhere else in the market. Large-cap companies tend to term out their debt for years at fixed rates and carry investment-grade credit ratings that keep borrowing costs manageable even when the Fed holds rates higher for longer. Small caps don’t have that luxury. They borrow shorter, they borrow at higher spreads to begin with, and a much larger share of that borrowing floats with prevailing rates. When the Fed moves, small-cap balance sheets feel it first and feel it hardest.

That’s exactly why this rally has been happening in a market environment that should, in theory, be working against it. The Fed under Chair Kevin Warsh has taken a notably hawkish posture this year, and traders have spent recent months pricing in the possibility of an actual rate increase rather than the cuts most investors expected heading into 2026. Small caps have rallied anyway, which tells you the earnings growth story has been strong enough to outrun the rate pressure so far.

The risk is what happens if that earnings momentum slows while rates stay elevated or move higher. A company with debt priced at a wide spread over a floating benchmark doesn’t get relief just because its revenue is growing. If margins compress at all, from wage inflation, input costs, or slowing demand, the interest bill doesn’t shrink to match. It’s the same amount of debt service pulled from a smaller pool of operating income, and at 31% of EBITDA already, there isn’t a lot of room to absorb a shock before it starts showing up in earnings per share. Nearly 40% of Russell 2000 companies are already unprofitable, which leaves a meaningful chunk of the index with even less cushion.

The Fed’s next meeting lands July 28-29, and it’s arguably a more important date for small-cap investors than for the broader market. A hold or a dovish tone gives the current rally room to keep running. A hike, or even language that keeps a hike on the table for the fall, tightens the exact pressure point that’s already the most fragile part of the small-cap balance sheet. For anyone riding this year’s small-cap strength, the momentum is real, but so is the leverage sitting underneath it.

Chemomab and Scipher Merge to Bring AI-Guided Precision Medicine to Rheumatoid Arthritis

Posted on July 8, 2026July 8, 2026 by [email protected]

Two small-cap biotechs are betting that artificial intelligence can succeed where a decade of drug development has stalled. Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine announced this morning that they have entered into a definitive merger agreement, combining Chemomab’s clinical-stage antibody nebokitug with Scipher’s AI-powered precision medicine platform to attack rheumatoid arthritis from a completely different angle than anything currently on the market.

The numbers explain why this matters. No new mechanism of action has been approved for rheumatoid arthritis since 2012, and no new branded therapy has reached the market since 2019. Only about a third of RA patients achieve low disease activity on current treatments, and the two leading drug classes now carry FDA boxed warnings. It’s a $24 billion market that has effectively been standing still for over a decade while patients cycle through drugs that only partially work.

Chemomab’s contribution is nebokitug, a first-in-class antibody that blocks CCL24, a protein tied to both inflammation and fibrosis. That dual mechanism is the differentiator. Most RA drugs on the market today only address inflammation, leaving the fibrotic, tissue-scarring side of the disease untouched. Nebokitug has already produced positive results across five clinical trials, including a Phase 2 study in primary sclerosing cholangitis that hit its safety endpoint and improved a range of fibrosis-related markers.

Scipher brings the half of the equation that makes this deal genuinely interesting. The company’s AI Network Medicine platform independently ranked CCL24 as the top therapeutic target for RA, arriving at the same conclusion Chemomab had reached through years of bench research, but from a completely different direction. Scipher also owns PrismRA, the only rheumatoid arthritis test with Medicare and Medicaid reimbursement approval for predicting how a patient will respond to treatment. That test will be used to select patients for the upcoming Phase 2 trial, meaning the study isn’t just testing whether nebokitug works. It’s testing whether AI-selected patients respond better than an unselected population, which is precisely the kind of precision-medicine proof point regulators and physicians have been waiting for.

Under the deal terms, the combined company will operate as Scipher Medicine Corporation and trade under the ticker SCIP. Scipher shareholders will hold roughly 68% of the combined entity, with Chemomab shareholders holding about 32% plus contingent value rights tied to nebokitug milestones. A syndicate led by Northpond Ventures, with Khosla Ventures, Blue Owl Healthcare Opportunities, and Neuberger funds participating, is putting in $30 million to fund the combined company. That capital, together with existing cash, is expected to carry operations into the second half of 2028, well past the Phase 2 readout expected in the first half of that year.

The deal values the combined company at $150 million before the new financing, a modest figure for a company sitting on a potential first-in-market precision medicine therapy for a disease affecting more than 20 million people worldwide. Scipher also brings existing revenue through biopharma partnerships and its immunology data business, giving the combined company more than one path to funding its pipeline while the RA trial plays out.

The transaction still needs shareholder approval from both companies and an SEC-cleared S-4 registration statement, with closing targeted for the fourth quarter of 2026.

Commercial Vehicle Group (CVGI) – First Raise Under Capital on Demand Agreement

Posted on July 8, 2026July 8, 2026 by [email protected]

Wednesday, July 08, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First Raise. Commercial Vehicle Group reported that it has made the first raise under the recently announced $25 million Capital on Demand agreement. As of June 29, 2026, the Company had sold 2.6 million shares of common stock in the ATM Program, generating net proceeds of approximately $11.6 million.

Use of Proceeds. As required by the Company’s secured term loan facility, all net proceeds were used by the Company to pay down outstanding indebtedness and the associated prepayment premium under the facility. As we noted previously, as of June 17, 2026, outstanding indebtedness under the Term Loan was $80 million. The Term Loan matures in June 2030 with a current interest rate of 13.47%. Any reduction in the outstanding loan balance is a positive for the Company, in our view, not only reducing high-cost debt but also eventually providing additional financial flexibility.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

FreightCar America (RAIL) – Strong Order Activity Reinforces Outlook

Posted on July 8, 2026July 8, 2026 by [email protected]

Wednesday, July 08, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Commercial momentum. FreightCar America secured a multi-year order for 1,900 railcars from a key customer, with deliveries scheduled through 2028. Combined with approximately 3,000 railcars ordered during the second quarter valued at roughly $300 million, the multi-year order highlights strong commercial demand and improves long-term backlog visibility.

Broad Customer Demand. Second quarter orders were received across all core market segments and included both new and existing customers, demonstrating the company’s expanding commercial reach and diversified product portfolio. The order activity reflects growing confidence in RAIL’s engineering expertise, manufacturing flexibility, and ability to execute reliably.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

The Real AI Trade Nobody’s Talking About: Why Data Center Cooling Just Became a Billion-Dollar Business

Posted on July 8, 2026July 8, 2026 by [email protected]

Ecolab just paid $4.75 billion in cash for a Calgary-based company most investors have never heard of, and that single transaction tells you more about where AI infrastructure spending is headed than almost anything happening in chips right now.

The March 2026 acquisition of CoolIT Systems came at a price of 29 times next-twelve-months adjusted EBITDA. That is not the kind of multiple a serious industrial buyer pays on a whim. It’s a signal that liquid cooling has moved from a nice-to-have into a required piece of the AI data center stack, and Ecolab is not the only one who has figured that out.

The math behind the move is simple physics more than anything else. Modern AI training runs on GPU servers packed with far more processing density than traditional data centers were ever built to handle, and that density generates heat that conventional air cooling simply cannot dissipate fast enough. Nvidia’s newest Blackwell racks push thermal loads that force operators into direct-to-chip cooling, rear-door heat exchangers, or full immersion systems just to keep the hardware running. ASHRAE’s 2026 AI Data Center Energy Performance Framework now names these approaches explicitly as requirements, not options, for high-density AI deployments. MarketsandMarkets pegs the global liquid cooling market at $4.07 billion this year, growing to $27.65 billion by 2033, a 31.5% annual growth rate that would make most industries jealous.

Ecolab’s purchase of CoolIT is just the most recent entry in a run of consolidation that has been building for over a year. Trane Technologies has announced plans to acquire LiquidStack. Schneider Electric bought Motivair in 2025 specifically to build out its liquid cooling capabilities. Vertiv closed its acquisition of ThermoKey on June 12 and opened a new manufacturing facility in Malaysia on July 1 just to keep up with AI infrastructure orders. Every major player in industrial thermal management has either bought a specialist in this space or announced plans to. When that many strategic acquirers are willing to pay near 30 times forward earnings for private cooling companies, the public small and micro-cap names sitting in the same value chain tend to get repriced whether or not they’re involved in a deal themselves.

A handful of small-cap names sit right in the middle of this shift. Modine Manufacturing has spent the last three years transforming itself from a legacy automotive parts supplier into a company focused on data center thermal management, divesting older auto businesses along the way to sharpen that story. Limbach Holdings has leaned into the build-out from a different angle, highlighting its modular construction and prefabrication platform for data centers in a June announcement that positions the company squarely inside the high-density projects hyperscalers are commissioning right now. And nVent Electric, which has spent more than a decade building liquid cooling distribution and high-density power systems, saw organic orders jump roughly 65% in a recent quarter driven almost entirely by large cooling orders tied to hyperscaler programs. The company has already deployed more than a gigawatt of cooling capacity across its installed base.

The AI investment story so far has mostly been about chips, and understandably so. But chips are useless if you can’t keep them cool enough to run at full capacity, and that second half of the equation is where the next wave of investment dollars appears to be heading. Power, water, and industrial thermal management are becoming just as important to the AI buildout as the silicon itself, and the M&A activity happening right now is the clearest evidence yet that the biggest names in industrial equipment already see it that way. Modine, Limbach, and nVent aren’t household names, and that’s exactly the point. When a $77 billion company pays nearly $5 billion for a private cooling specialist, the small-cap names doing similar work for the same customers are the ones worth watching next.

Michael Burry Bets Against Micron After Its Best Quarter Ever. Is the AI Memory Boom About to Bust?

Posted on July 7, 2026July 7, 2026 by [email protected]

Michael Burry just shorted one of the best-performing stocks in the market, and the reasoning behind it is worth understanding whether you own semiconductor stocks or not.

The Scion Asset Management founder disclosed a new short position in Micron Technology (NASDAQ: MU) in a Substack post on July 2, entering at $1,051.87 per share. The stock dropped roughly 5.5% on the news, closing at $975.56. Burry also holds existing short positions in Nvidia, Applied Materials, and the iShares Semiconductor ETF (SOXX), and has said publicly that AI-related chip stocks could see a 30% correction from here.

Burry’s argument centers on one word: cyclicality. “Micron defines cyclical like no other,” he wrote, and he backed it up with numbers that are hard to wave away. The stock has suffered 34 drawdowns of more than 30% over the past 42 years. Its median return on invested capital sits at just 4%. Median return on equity comes in at 7%, which Burry called “frankly terrible.” Free cash flow has gone negative in 48% of quarters historically. And right now, Micron is trading further above its 200-day moving average than at any point since 1984, a stretch that includes the dot-com bubble. Burry dismissed the high-bandwidth memory business fueling the current rally as “just another in a very long series” of Micron products rather than a durable competitive edge.

It’s a compelling case built on four decades of history. The problem is that Micron’s most recent quarter does not look like the start of a downturn. For the period ending May 2026, the company posted $41.5 billion in revenue, up 345.7% year over year, with gross margin expanding to 84.6% from 37.7% a year earlier. On the June 24 earnings call, Chief Business Officer Sumit Sadana said customer demand for memory chips remains “well above our ability to supply” across nearly every product category through 2028. Long-term supply contracts, some running five years with prepayments attached, now account for at least half of the company’s revenue. That is not the profile of a business quietly cracking under the weight of a boom-and-bust cycle. It looks like a company locking in demand years in advance.

So which read is right? The piece of Burry’s argument that deserves the most attention isn’t the historical volatility data, it’s what he pointed to as the actual catalyst. South Korea recently announced mega semiconductor projects worth at least 1.35 trillion won, roughly $880 billion, including new fabrication plants from Samsung and SK Hynix. Burry called this “the beginning of the end.” Samsung, SK Hynix, and Micron together control close to 90% of the global DRAM market. When two of the three dominant players start committing hundreds of billions of dollars to new capacity, the pricing power that has driven this year’s memory rally typically doesn’t last forever. Supply eventually catches up to demand, and when it does in this industry, it tends to overshoot.

That dynamic is becoming more real by the day. SK Hynix debuted its U.S. listing today, raising approximately $28 billion in fresh capital, much of which is aimed squarely at expanding memory production capacity. Meanwhile, insiders at Micron have sold $124.9 million worth of shares over the past three months, a detail that doesn’t prove anything on its own but is worth filing away.

None of this settles the debate, and it shouldn’t. Micron is not a small or micro-cap company, but the memory supply chain it sits atop runs through dozens of smaller public names in testing, packaging, specialty materials, and thermal management, all of which trade on the same underlying cycle. When one of the most recognizable short sellers in the market publicly challenges the sustainability of an AI-driven supercycle in the exact stock that anchors that supply chain, the ripple effects extend well past Micron’s own share price. Investors holding exposure anywhere in the memory ecosystem now have a credible bear case sitting alongside the bull case, and the coming quarters, particularly how HBM pricing holds up against the wave of new South Korean capacity, will likely determine who was right.